article thumbnail

Episode 28 – A CEO Leading a MedTech Company Through Covid

Medical Device Success

Reading time: 2 – 3 minutes In January 2018 when Dominik Beck took the helm of Rudolf Riester, GmbH, he began executing a plan to put Riester in a more competitive position against its larger rivals. Then in early 2020 Covid spread across the world. But to take advantage of an opportunity, you have to execute.

Leads 100
article thumbnail

Pharma is big business whose goal is to maximize shareholder value

World of DTC Marketing

From 2016 to 2020, the 14 leading drug companies spent $577 billion on stock buybacks and dividends—$56 billion more than they spent on R&D over the same period.” One company, Amgen, spent nearly six times as much on buybacks, dividends, and executive compensation as it did on R&D in 2018. Big pharma is big business.

Pharma 292
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

8 Ways to Enhance the Patient Experience & Drive Leads with QR Codes

Healthcare Success

Ready to start leveraging QR code technology and stay ahead of your competition? In this blog post, you’ll learn: Why QR codes have made a comeback, When to use them, And, 8 ways to improve the patient experience and drive leads with QR codes. . 8 Ways to Improve the Patient Experience & Drive Leads with QR Codes.

Leads 112
article thumbnail

8 Ways to Enhance the Patient Experience & Drive Leads with QR Codes

Healthcare Success

Ready to start leveraging QR code technology and stay ahead of your competition? In this blog post, you’ll learn: Why QR codes have made a comeback, When to use them, And, 8 ways to improve the patient experience and drive leads with QR codes. . 8 Ways to Improve the Patient Experience & Drive Leads with QR Codes.

Leads 52
article thumbnail

Clovis warns of insolvency as Rubraca goes into reverse

pharmaphorum

However, turnover fell back to $148 million in 2021, mainly as a result of strong competition from AstraZeneca and Merck & Co’s class-leading Lynparza (olaparib) – which has a much broader product label – as well as GSK’s Zejula (niraparib). With finances tight, Clovis has deferred a $1.9

article thumbnail

Comparison of Humira biosimilars in the US and Europe

Pharmaceutical Technology

Biosimilars are an important tool to facilitate competition, lower the price of drugs, and create savings across the board. For example, the cost of Humira biosimilars in Denmark decreased by 82% from September 2018 to December 2018. Biosimilars launched in the US have seen slow uptake due to several reasons.

article thumbnail

Digital transformation to drive biomanufacturing market

European Pharmaceutical Review

Influencing factors identified in the report include higher competition, competitive pricing and inflation rate, technological advancements and evolving regulatory guidelines. These factors have led to industry 4.0 technologies.